Erratum: Making progress in treating multiple myeloma with total therapies: Issue of complete remission and more (Leukemia (2008) 10.1038/leu.2008.40);Making progress in treating multiple myeloma with total therapies: Issue of complete remission and more

Leukemia

Volumn 22, Issue 8, 2008, Pages 1633-1636

  Barlogie, B ^a   van Rhee, F ^a   Shaughnessy Jr , J D ^a   Anaissie, E ^a   Crowley, J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LONG TERM CARE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 49449085862     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.86     Document Type: Erratum

References (17)

1. Bergsagel L. A kinder, gentler way: Control of the proliferative tumour compartment, not cosmetic complete response, should be the goal of myeloma therapy. 2008; (In press).
2. Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008; e-pub ahead of print 17 January 2008.
3. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
4. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ et al Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
5. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-1356.
6. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R et al. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-956.
7. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
8. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164.
9. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
10. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, Van Rhee F et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: Comparison with total therapy 2. Br J Haematol 2007; In press.
11. Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393-399.
12. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692-1700.
13. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
14. Haessler J, JD SJ, Zhan F, Crowley J, Epstein J, van Rhee F et al. Benefit of complete response in multiple myeloma limited to highrisk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073-7079.
15. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
16. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr JD et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121-1128.
17. Barlogie B, Tricot G. Complete response in myeloma: A Trojan horse? Blood 2006; 108: 2134.